ORIC Pharmaceuticals Inc ORIC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
-
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
-
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
-
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
-
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $13.63
- Day Range
- $12.73–13.49
- 52-Week Range
- $7.23–14.68
- Bid/Ask
- $12.36 / $14.50
- Shares Outstanding
- 103.65M
- Market Cap
- $1.37B
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 111
- Website
- https://www.oricpharma.com
Valuation
|
Metric
|
ORIC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.58 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ORIC
|
|---|---|
Quick Ratio | 12.76 |
Current Ratio | 13.19 |
Interest Coverage | — |
Quick Ratio
ORIC
Profitability
|
Metric
|
ORIC
|
|---|---|
Return on Assets (Normalized) | −28.21% |
Return on Equity (Normalized) | −29.93% |
Return on Invested Capital (Normalized) | −29.67% |
Return on Assets
ORIC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|P<HR&PC | LOCK|?&d!! | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j@^GZs | LOCK|Qv^B | $83B | |||
| Moderna Inc
MRNA
| LOCK|>f?>Tz? | LOCK|c& | $80B | |||
| argenx SE ADR
ARGX
| LOCK|h$?h@CX | LOCK|%< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$&dzT!y | LOCK|q&v | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kKMZb< | LOCK|Y$rX | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|rTk^<$v | LOCK|&^XC | $28B | |||
| Incyte Corp
INCY
| LOCK|cwm>>pl | LOCK|@?q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z#H<L?& | LOCK|r& | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|CVw?$%% | LOCK|FG | $14B |
United States